Article
Combined treatment with silibinin and epidermal growth factor receptor tyrosine kinase inhibitors overcomes drug resistance caused by T790M mutation.
Molecular cancer therapeutics - 1 Dec 2010
Rho Jin Kyung, Choi Yun Jung, Jeon Byung-Suk, Choi Su Jin, Cheon Gi Jeong, Woo Sang-Keun, Kim Hye-Ryoun, Kim Cheol Hyeon, Choi Chang-Min, Lee Jae Cheol
Abstract excerpt
Although epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI) produce an initially dramatic response in lung cancer patients harboring a mutation in the EGFR gene, development of acquired resistance is almost inevitable. A secondary mutation of threonine 790 (T790M) is associated with approximately half of the cases of acquired resistance. This study investigated whether the addition of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.